GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Gross-Profit-to-Asset %

Changzhou Qianhong Biopharma Co (SZSE:002550) Gross-Profit-to-Asset % : 33.95% (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Changzhou Qianhong Biopharma Co's annualized Gross Profit for the quarter that ended in Mar. 2025 was ¥981 Mil. Changzhou Qianhong Biopharma Co's average Total Assets over the quarter that ended in Mar. 2025 was ¥2,889 Mil. Therefore, Changzhou Qianhong Biopharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 33.95%.


Changzhou Qianhong Biopharma Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Gross-Profit-to-Asset % Chart

Changzhou Qianhong Biopharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.48 33.61 33.46 28.17 29.92

Changzhou Qianhong Biopharma Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.67 30.73 29.88 26.44 33.95

Competitive Comparison of Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset % falls into.


;
;

Changzhou Qianhong Biopharma Co Gross-Profit-to-Asset % Calculation

Changzhou Qianhong Biopharma Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=837.176/( (2766.081+2830.441)/ 2 )
=837.176/2798.261
=29.92 %

Changzhou Qianhong Biopharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=981.036/( (2830.441+2948.304)/ 2 )
=981.036/2889.3725
=33.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Changzhou Qianhong Biopharma Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Changzhou Qianhong Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.
Executives
Huang Jie Executives
Wang Ke Directors, executives
Jiang Wen Qun Supervisors
Zou Shao Bo Executives
Wei Li Jun Executives
Mei Chun Wei Executives
Zhou Xiang Directors, executives
Zhao Gang Director
Ye Hong Ping Executives
Liu Jun Director
Fan Yong Executives
Jiang Jian Ping Supervisors
Wang Yao Fang Director
Hai Tao Directors, executives
Wang Yi Director

Changzhou Qianhong Biopharma Co Headlines

No Headlines